Kinetics of Immune Subsets in COVID-19 Patients Treated with Corticosteroids.

Autor: Pappas AG; 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, 'Evangelismos' General Hospital, 10676 Athens, Greece.; Intensive Care Unit, 'G. Gennimatas' General Hospital, 11527 Athens, Greece.; COVID-19 Unit, 'Evangelismos' General Hospital, 10676 Athens, Greece., Chaliasou AL; COVID-19 Unit, 'Evangelismos' General Hospital, 10676 Athens, Greece.; 4th Department of Internal Medicine, 'Evangelismos' General Hospital, 10676 Athens, Greece., Panagopoulos A; COVID-19 Unit, 'Evangelismos' General Hospital, 10676 Athens, Greece.; 3rd Department of Internal Medicine, 'Evangelismos' General Hospital, 10676 Athens, Greece., Dede K; 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, 'Evangelismos' General Hospital, 10676 Athens, Greece., Daskalopoulou S; COVID-19 Unit, 'Evangelismos' General Hospital, 10676 Athens, Greece.; 5th Department of Internal Medicine, 'Evangelismos' General Hospital, 10676 Athens, Greece., Moniem E; COVID-19 Unit, 'Evangelismos' General Hospital, 10676 Athens, Greece.; 5th Department of Internal Medicine, 'Evangelismos' General Hospital, 10676 Athens, Greece., Polydora E; 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, 'Evangelismos' General Hospital, 10676 Athens, Greece.; COVID-19 Unit, 'Evangelismos' General Hospital, 10676 Athens, Greece., Grigoriou E; Department of Immunology-Histocompatibility, 'Evangelismos' General Hospital, 10676 Athens, Greece., Psarra K; Department of Immunology-Histocompatibility, 'Evangelismos' General Hospital, 10676 Athens, Greece., Tsirogianni A; Department of Immunology-Histocompatibility, 'Evangelismos' General Hospital, 10676 Athens, Greece., Kalomenidis I; 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, 'Evangelismos' General Hospital, 10676 Athens, Greece.; COVID-19 Unit, 'Evangelismos' General Hospital, 10676 Athens, Greece.
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2022 Dec 24; Vol. 15 (1). Date of Electronic Publication: 2022 Dec 24.
DOI: 10.3390/v15010051
Abstrakt: Rationale: Changes in anti-SARS-CoV-2 defense immune subsets in patients treated with dexamethasone (DXM) for severe COVID-19 and their relation to disease outcomes are poorly understood.
Methods: Blood-lymphocyte subsets of 110 hospitalized COVID-19 patients were prospectively examined. A first sample was taken at enrollment and a second one 7-10 days later. Total B-, T-lymphocytes, CD4+, CD8+, T-regulatory (Treg), Natural-Killer (NK) and NK T-cells were counted using flow cytometry.
Results: At enrollment, patients with respiratory failure, characterized by DXM failure (intubation/death) or DXM success (hospital discharge) exhibited significantly fewer CD3+, CD4+ and CD8+ cells and B-lymphocytes compared to the control group (no respiratory failure/no DXM). At the time of treatment completion, the DXM-failure group exhibited significantly fewer CD3+, CD4+ and CD8+ cells, memory CD4+ and CD8+ T-lymphocytes, compared to the control and the DXM-success groups and fewer activated CD4+ T-lymphocytes, Tregs and NK cells compared to the control group. At the time of treatment completion, the number of all investigated lymphocyte subsets increased in the DXM-success group and was similar to those of the control group. NK cells significantly decreased over time in the DXM-failure group.
Conclusion: The lymphocyte kinetics differ between DXM-treated and control COVID-19 patients and are associated with clinical outcomes.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje